126 related articles for article (PubMed ID: 35461090)
21. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
[TBL] [Abstract][Full Text] [Related]
22. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
23. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models.
Li Y; Williams ME; Cousar JB; Pawluczkowycz AW; Lindorfer MA; Taylor RP
J Immunol; 2007 Sep; 179(6):4263-71. PubMed ID: 17785867
[TBL] [Abstract][Full Text] [Related]
24. Primary central nervous system lymphoma: current state of anti-CD20 therapy and appraisal of reported response criteria.
Siegal T
J Clin Neurosci; 2014 May; 21(5):709-15. PubMed ID: 24725453
[TBL] [Abstract][Full Text] [Related]
25. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
26. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
27. Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts.
Ghetie MA; Crank M; Kufert S; Pop I; Vitetta E
J Immunother; 2006; 29(5):536-44. PubMed ID: 16971809
[TBL] [Abstract][Full Text] [Related]
28. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.
Feugier P
Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779
[TBL] [Abstract][Full Text] [Related]
29. Combination of
Repetto-Llamazares AHV; Malenge MM; O'Shea A; Eiríksdóttir B; Stokke T; Larsen RH; Dahle J
Eur J Haematol; 2018 Oct; 101(4):522-531. PubMed ID: 29993152
[TBL] [Abstract][Full Text] [Related]
30. Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.
Muldoon LL; Lewin SJ; Dósa E; Kraemer DF; Pagel MA; Doolittle ND; Neuwelt EA
Clin Cancer Res; 2011 Apr; 17(8):2207-15. PubMed ID: 21385922
[TBL] [Abstract][Full Text] [Related]
31. Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity.
Li HF; Wu C; Chen T; Zhang G; Zhao H; Ke CH; Xu Z
Int J Nanomedicine; 2015; 10():4783-96. PubMed ID: 26257518
[TBL] [Abstract][Full Text] [Related]
32. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.
Xuan C; Steward KK; Timmerman JM; Morrison SL
Blood; 2010 Apr; 115(14):2864-71. PubMed ID: 20139095
[TBL] [Abstract][Full Text] [Related]
33. Current perspective on rituximab in rheumatic diseases.
Schioppo T; Ingegnoli F
Drug Des Devel Ther; 2017; 11():2891-2904. PubMed ID: 29042750
[TBL] [Abstract][Full Text] [Related]
34. Increased proportion of CD20+ T cells after rituximab treatment in patient with neuromyelitis optica later diagnosed with lung B-cell lymphoma: A case report.
Lee JK; Kwon S; Han JH; Yoon SE; Kim BJ; Kang ES
J Neuroimmunol; 2021 Jun; 355():577564. PubMed ID: 33862419
[TBL] [Abstract][Full Text] [Related]
35. Novel reduction-sensitive micellar nanoparticles assembled from Rituximab-doxorubicin conjugates as smart and intuitive drug delivery systems for the treatment of non-Hodgkin's lymphoma.
Yin H; Meng T; Shu L; Mao M; Zhou L; Chen H; Song D
Chem Biol Drug Des; 2017 Nov; 90(5):892-899. PubMed ID: 28440948
[TBL] [Abstract][Full Text] [Related]
36. Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.
Vincent M; Teppaz G; Lajoie L; Solé V; Bessard A; Maillasson M; Loisel S; Béchard D; Clémenceau B; Thibault G; Garrigue-Antar L; Jacques Y; Quéméner A
MAbs; 2014; 6(4):1026-37. PubMed ID: 25072059
[TBL] [Abstract][Full Text] [Related]
37. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.
Nijmeijer BA; van Schie ML; Halkes CJ; Griffioen M; Willemze R; Falkenburg JH
Blood; 2010 Dec; 116(26):5930-40. PubMed ID: 20844239
[TBL] [Abstract][Full Text] [Related]
38. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
40. The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody.
Nahimana A; Aubry D; Breton CS; Majjigapu SR; Sordat B; Vogel P; Duchosal MA
Leuk Lymphoma; 2014 Sep; 55(9):2141-50. PubMed ID: 24283753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
